Clinical Heterogeneity of Patients With Antinuclear Matrix Protein 2 Antibody–Positive Myositis: A Retrospective Cohort Study in China

References

1. 1.↵
   1. Stuhlmüller B,
   2. Schneider U,
   3. González-González JB,
   4. Feist E

   . Disease specific autoantibodies in idiopathic inflammatory myopathies. Front Neurol 2019;10:438.

   OpenUrl
2. 2.↵
   1. Li L,
   2. Wang H,
   3. Wang Q, et al

   . Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. J Neurol Sci 2019;397:123-8.

   OpenUrlCrossRef
3. 3.↵
   1. Li S,
   2. Ge Y,
   3. Yang H, et al

   . The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Clin Rheumatol 2019;38:2171-9.

   OpenUrl
4. 4.↵
   1. Hoogendijk JE,
   2. Amato AA,
   3. Lecky BR, et al

   . 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands. Neuromuscul Disord 2004;14:337-45.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Mammen AL,
   2. Allenbach Y,
   3. Stenzel W,
   4. Benveniste O, ENMC 239th Workshop Study Group

   . 239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord 2020;30:70-92.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. DeWane ME,
   2. Waldman R,
   3. Lu J

   . Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 2020;82:267-81.

   OpenUrl
7. 7.↵
   1. Albayda J,
   2. Pinal-Fernandez I,
   3. Huang W, et al

   . Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res 2017;69:1771-6.

   OpenUrlPubMed
8. 8.↵
   1. Satoh M,
   2. Tanaka S,
   3. Ceribelli A,
   4. Calise SJ,
   5. Chan EKL

   . A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52:1-19.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Inoue M,
   2. Tanboon J,
   3. Hirakawa S, et al

   . Association of dermatomyositis sine dermatitis and with anti-nuclear matrix protein 2 autoantibodies. JAMA Neurol 2020;77:872-7.

   OpenUrl
10. 10.↵
    1. Ichimura Y,
    2. Matsushita T,
    3. Hamaguchi Y, et al

    . Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012;71:710-3.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Yang H,
    2. Peng Q,
    3. Yin L, et al

    . Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 2017;19:259.

    OpenUrl
12. 12.↵
    1. Lu X,
    2. Peng Q,
    3. Wang G

    . The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. Curr Opin Rheumatol 2019;31:643-9.

    OpenUrl
13. 13.↵
    1. Lian X,
    2. Zou J,
    3. Guo Q, et al

    . Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. Chest 2020;158:1535-45.

    OpenUrlPubMed
14. 14.↵
    1. De Bleecker JL,
    2. De Paepe B,
    3. Aronica E, et al

    . 205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies Part II, 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord 2015;25:268-72.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Betteridge Z,
    2. Tansley S,
    3. Shaddick G, et al

    . Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019;101:48-55.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Liu Y,
    2. Zheng Y,
    3. Gang Q, et al

    . Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies. Eur J Neurol 2020;27:514-21.

    OpenUrl
17. 17.↵
    1. Moghadam-Kia S,
    2. Oddis CV,
    3. Aggarwal R

    . Anti-MDA5 antibody spectrum in Western world. Curr Rheumatol Rep 2018;20:78.

    OpenUrlPubMed
18. 18.↵
    1. Zhong L,
    2. Yu Z,
    3. Song H

    . Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: a meta-analysis of 20 cohorts. Clin Immunol 2019;198:11-8.

    OpenUrl
19. 19.↵
    1. Chung MP,
    2. Richardson C,
    3. Kirakossian D, et al

    . Calcinosis biomarkers in adult and juvenile dermatomyositis. Autoimmun Rev 2020;19:102533.

    OpenUrl
20. 20.↵
    1. Wang L,
    2. Huang L,
    3. Yang Y, et al

    . Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay. Clin Rheumatol 2018;37:2731-9.

    OpenUrl
21. 21.↵
    1. Bermudez J,
    2. Heim X,
    3. Bertin D, et al

    . Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series. Expert Rev Respir Med 2020;14:845-50.

    OpenUrl
22. 22.
    1. Rogers A,
    2. Chung L,
    3. Li S,
    4. Casciola-Rosen L,
    5. Fiorentino DF

    . Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res 2017;69:1909-14.

    OpenUrl
23. 23.↵
    1. Long K,
    2. Danoff SK

    . Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med 2019;40:561-72.

    OpenUrl
24. 24.↵
    1. Ahuja J,
    2. Arora D,
    3. Kanne JP,
    4. Henry TS,
    5. Godwin JD

    . Imaging of pulmonary manifestations of connective tissue diseases. Radiol Clin North Am 2016;54:1015-31.

    OpenUrl
25. 25.↵
    1. Zuo Y,
    2. Ye L,
    3. Liu M, et al

    . Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology 2020;59:2829-37.

    OpenUrl
26. 26.↵
    1. Motegi SI,
    2. Sekiguchi A,
    3. Toki S, et al

    . Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol 2019;29:511-7.

    OpenUrl
27. 27.↵
    1. Romero-Bueno F,
    2. Diaz Del Campo P,
    3. Trallero-Araguás E, et al

    . Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 2020;50:776-90.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Fiorentino DF,
    2. Chung LS,
    3. Christopher-Stine L, et al

    . Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013;65:2954-62.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Cavazzana I,
    2. Fredi M,
    3. Ceribelli A, et al

    . Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 2016;433:1-5.

    OpenUrlCrossRef